column
Select articles
Clinical efficacy of immunotherapy plus target therapy in the treatment of postoperative recurrence of ruptured hepatocellular carcinoma
2021, 20(102): 1-4. DOI: 10.3760/cma.j.cn115610-20210625-00311
Abstract PDF
Clinical efficacy of first‐line treatment of atelizumab plus bevacizumab for recurrent hepato‐ cellular carcinoma after operation
2021, 20(102): 5-9. DOI: 10.3760/cma.j.cn115610-20211105-00544
Abstract PDF
Clinical efficacy of immunotherapy plus targeted therapy in the treatment of postoperative recurrence for hepatocellular carcinoma with bile duct tumor thrombus
2021, 20(102): 10-14. DOI: ：10.3760/cma.j.cn115610-20210907-00445
Abstract PDF
Clinical efficacy of first-line immunotherapy plus anti-angiogenesis targeted therapy in the treatment of advanced hepatocellular carcinoma
2021, 20(102): 15-19. DOI: 10.3760/cma.j.cn115610-20210628-00316
Abstract PDF
Clinical efficacy of atezolizumab plus bevacizumab for first‐line treatment of unresectable hepatocellular carcinoma
2021, 20(102): 20-25. DOI: 10.3760/cma.j.cn115610-20210629-00318
Abstract PDF
Clinical efficacy of atezolizumab plus bevacizumab in the first-line treatment of advanced hepatocellular carcinoma
2021, 20(102): 25-28. DOI: 10.3760/cma.j.cn115610-20211112-00563
Abstract PDF
Clinical efficacy of atezolizumab plus bevacizumab for the treatment of advanced hepatocellular carcinoma
2021, 20(102): 29-31. DOI: 10.3760/cma.j.cn115610-20210703-00327
Abstract PDF
Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy in the treatment of advanced hepatocellular carcinoma
2021, 20(102): 32-36. DOI: ：10.3760/cma.j.cn115610-20210630-00324
Abstract PDF
Clinical efficacy of transarterial chemoembolization combined with immunotherapy plus target therapy for advanced unresectable intrahepatic cholangiocarcinoma
2021, 20(102): 37-40. DOI: 10.3760/cma.j.cn115610-20211108-00551
Abstract PDF

Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy for advanced hepatocellular carcinoma
2021, 20(102): 41-44. DOI: 10.3760/cma.j.cn115610-20211104-00543
Abstract PDF
Clinical efficacy of restart immunotherapy for advanced hepatocellular carcinoma
2021, 20(102): 45-48. DOI: 10.3760/cma.j.cn115610-20211107-00547
Abstract PDF